NovaBridge Biosciences (NBP) Form 6-K — Oct 13, 2026
NovaBridge Biosciences' majority-owned subsidiary Visara entered an exclusive license with Wuhan Hiteck Biological Pharma for VIS-102 (HT006.2.2), a next-generation recombinant human nerve growth factor therapy for neurotrophic keratitis, with worldwide rights excluding Greater China. Visara will pay $7.0 million upfront plus up to $104.0 million in development and commercialization milestones, plus tiered single-digit royalties on net sales. The deal gives Visara a second clinical-stage program, expanding beyond retinal vascular disease (VIS-101) into ocular surface disease.
Key figures
- Upfront Payment Usd
- 7000000
- Milestone Payments Usd
- 104000000
- Phase1b crossover healing
- 43%
- Phase1b complete healing highest dose
- 50%
- Phase1b complete healing vehicle week4
- 14%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.